Tracking the Supply Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tracking the Supply Chain
As the battle against counterfeits gains momentum, PharmTech speaks to Mark Davison, CEO of Blue Sphere Health, and Craig Stobie, global life sciences sector manager at Domino Printing Sciences, about the challenges involved with coding and tracking drugs through the global supply chain. Potential solutions are discussed, including fingerprinting technologies and end-user verification.


Pharmaceutical Technology
Volume 36, Issue 12

PharmTech: What challenges still exist in terms of coding and tracing drugs reliably and securely through the global supply chain?

Davison: One key issue for manufacturers is harmonisation of standards. The uncertainty in timing and variation in technical requirements worldwide is adding to the expense faced by manufacturers. Most major manufacturers must plan for multiple legal scenarios. On production lines, which might supply many different geographies, the most onerous coding regime determines the line configuration. An international coding convention would be a major step forward. GS1 standards provide one framework in terms of code formats, but the rules for which transactions need to be recorded and how data are stored and shared also need to be standardised.

Another key issue is ubiquity. How do we ensure that all countries have access to scanning equipment to check for counterfeits at the borders? There is a strong ‘network effect’ in product traceability—that is, the security of the system increases with the number of transactions that are verified. The logic of this approach is that we should involve developing countries in drug-traceability schemes as well as developed economies. In my view, one way to do this is by using mobile phone technology, which can empower billions of patients.

Stobie: The challenge regarding tracing drugs reliably and securely is that the problem is getting bigger with time. Pharmaceutical companies are working in an international environment, which is hard to moderate due to different regions presenting different challenges.

Coding and marking go quite a way towards building and operating a secure global supply chain, but need to be supported by other elements, such as risk assessment and management, to create a safe ‘whole supply chain’ picture.

There also needs to be more investment in technologies that support the coding and marking of drugs. It is ironic that, in most countries, a bottle of water can have more tamper-evident packaging than a 1000-oncology drug. Combining coding and marking with such strategies would be a huge help.

PharmTech: What new authentication technologies and system strategies can help to identify and prevent counterfeits?

Davison: The world is going mobile. It seems logical that this trend should be factored into product security strategies. The pharmaceutical industry still has an obligation to provide a secure supply chain, and there are new ways to enable authentication of codes, such as fingerprinting technologies. The industry must continue to invest in the safety of its supply chain. However, allowing the patient to verify their medicine as an additional last step gives millions of extra eyes and can provide excellent opportunities for data mining to discover patterns of counterfeiting. Consumer verification is proving to be very popular in the developing world. In India, in particular, the approach has been a useful addition to the arsenal of anticounterfeiting approaches. There are no easy answers to counterfeiting. It requires multiple layers of defence, concerted action by industry and constant vigilance by consumers.

Stobie: There are a handful of new authentication technologies and system strategies that can help to identify and prevent counterfeit medicines. A key one is mass serialisation. Although this technology comes with the associated challenge of reliable authentication, it can be highly effective in terms of offering producer to patient traceability and pinpointing risks. Other strategies that can help identify and prevent counterfeits are the inclusion of digital signatures, asymmetric encryption and covert features, which can be verified with a mobile phone.

Note

1. On Feb. 14, 2012, the media reported that counterfeit versions of Roche’s multibillion cancer drug, Avastin (bevacizumab 400mg/16mL), had been distributed in the United States.

Blue Sphere Health is a consultancy based in the United Kingdom, with a focus on global healthcare, pharmaceutical security, patient safety and anticounterfeiting. Domino Printing Sciences, a company specialised in coding, marking and printing technologies, formed an internal task force in 2011, dedicated to helping pharmaceutical manufactures comply with the new European Union’s Falsified Medicines Directive (FMD) that member states must begin implementing in Jan. 2, 2013.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here